GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...

The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Johnson & Johnson announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant announcements regarding its clinical trials, particularly the ANTHEM-UC ...

Commissions do not affect our editors' opinions or evaluations. Anthem Medicare Supplement plans offer cost-competitive choices for people who want to add coverage beyond what they receive with ...